Adam Jeffery News pharmaphorum welcomes George Underwood to its editorial helm With its focus always on top quality, engaging editorial content, pharmaphorum is pleased to announce that George Underwood has taken up the position of Features Editor, effective Dec 3rd Press releases Partner Content Predictions for 2019: Ten trends that will shape the future ... eBook Provides Biopharma Decision Makers With What’s Next Insights to Navigate Challenges and Capitalize on the Opportunities Ahead Digital The future of pharma in a digital world How is digital health impacting pharma? An exclusive live broadcast from Frontiers Health 2018 addressed this subject on 15 November. Partner Content Partner Content Leadership: Cultivating a Culture of High Curiosity The bar is set high for Medical Affairs (MA) talent: traditional capabilities are no longer sufficient to address Load more results
News pharmaphorum welcomes George Underwood to its editorial helm With its focus always on top quality, engaging editorial content, pharmaphorum is pleased to announce that George Underwood has taken up the position of Features Editor, effective Dec 3rd
Press releases Partner Content Predictions for 2019: Ten trends that will shape the future ... eBook Provides Biopharma Decision Makers With What’s Next Insights to Navigate Challenges and Capitalize on the Opportunities Ahead
Digital The future of pharma in a digital world How is digital health impacting pharma? An exclusive live broadcast from Frontiers Health 2018 addressed this subject on 15 November.
Partner Content Partner Content Leadership: Cultivating a Culture of High Curiosity The bar is set high for Medical Affairs (MA) talent: traditional capabilities are no longer sufficient to address
News Novo Nordisk slumps as it cuts sales forecast, names new CEO Novo Nordisk has a new CEO, facing an uphill battle to restore the fortunes of its US business as diabetes and obesity drugs come under pressure.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
